We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-7.50 | -0.44% | 1,697.50 | 1,697.00 | 1,697.50 | 1,711.00 | 1,695.50 | 1,705.00 | 456,657 | 09:05:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.22 | 70.07B |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2020 17:37 | Riz, Agree with Spud plus AZN now hugely overbought. May tumble tomorrow and come back to the 20 DMA. | beckers2008 | |
30/4/2020 17:35 | I read here that AZN and GSK were both together in the discovery of the corona virus Vaccine? | abdullla | |
30/4/2020 17:29 | Imo, no. All the value and then some is in it. It's p/e is more than 5x GSK. Plus the dividend is 50% less. spud | spud | |
30/4/2020 17:22 | Is it worth buying into azn? | riz000 | |
30/4/2020 17:18 | Not really surprised by the price action today. Decent results but the excitement and sentiment is elsewhere such as AZN.Does anyone remember when the demerger was slotted to happen? | rikky72 | |
30/4/2020 17:12 | Market manipulation is the game. | abdullla | |
30/4/2020 17:01 | Looked good at 2-30pm today rising 23p, then started to tumble very quickly! Difficult to understand why both of these trends occurred in such a short space of time. | jadeticl3 | |
30/4/2020 16:27 | AZN is flying after it admits that it has joined Oxford university to develop vaccine ready for use at the end of this year,this is world's first,BBC news now. | abdullla | |
30/4/2020 15:59 | Sellers always above 1700p. Had a great run, no harm profit taking, AstraZeneca is the one way over bought. | montyhedge | |
30/4/2020 15:13 | Inverse H&S? Buy at 1575 target 1775? | toffeeman | |
30/4/2020 15:09 | >1700p proving to be a bit of a struggle …. ;0) | tradermichael | |
30/4/2020 15:00 | It’s perhaps not surprising that the worth of healthcare companies should emerge during a global pandemic, but we should offer thanks for the UK’s big pharma twins – AstraZeneca and GlaxoSmithKline (continued) .... | zho | |
30/4/2020 14:56 | Looking at the so far pharma results it's quite clear that they are better than previous ones which proves that the drastic drop in the share price was unwarranted,the recent daily rises supports this factor. | abdullla | |
30/4/2020 12:28 | Yes TM free of COST but if you read between the lines you will find pumped up administration and manufacturing costs also. | abdullla | |
30/4/2020 12:04 | Not necessarily: Soriot also said there is agreement between companies within the pharmaceutical industry to help one another with production, and that the intention is to supply the vaccine free of charge during the pandemic. | tradermichael | |
30/4/2020 10:59 | AZN will fly with Oxford invented vaccine the reason behind the rise,"Astra possibly to manufacture and sell the Oxford University vaccine if it looks promising" | abdullla | |
30/4/2020 10:12 | Come GSK pull your finger out.... AZN keeps hitting ATH even though its on a much bigger p/e and lower growth rate than GSK. | igoe104 | |
30/4/2020 09:50 | This is rather frustrating. | eggy toast | |
30/4/2020 09:25 | AZN flying GSK finding it difficult to stay afloat why? | abdullla | |
30/4/2020 09:07 | FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status -- Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of BRCA mutational status, addressing a high unmet need in ovarian cancer -- New individualised starting dose based on the patient's baseline weight and/or platelet count approved for first-line maintenance treatment; lower rates of haematological adverse events were observed with the individualised dosing group | tradermichael | |
29/4/2020 20:32 | Vaccine worry on sales. Perhaps that why they are down.https://www.fie | montyhedge | |
29/4/2020 19:33 | Let's hope they have terrible results, share price tends rise then. | waikenchan | |
29/4/2020 17:43 | Guys keep an eye on Barclays, RBS and lloyds are my bet, | riz000 | |
29/4/2020 17:36 | Bloomberg reports that GlaxoSmithKline (NYSE:GSK) plans to sell its 5.7% stake in Hindustan Unilever Ltd. (NYSE:UL) via a series of block trades totaling $3.7B. The company received the equity this week as part of the payment for a recently completed sale of a portfolio of assets to Unilever that included health food drink brands in India and Bangladesh for $3.6B in cash plus the Hindustan stake. The precise timing of the sales has not been disclosed. | philanderer | |
29/4/2020 16:41 | My roof is leaking on close examination found GSK had gone through the roof !lol | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions